Study to Assess Safety, Tolerability and PK of AZD1480 in Patients With Solid Tumours

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE1

Total Enrollment

72 participants

Study Classification

INTERVENTIONAL

Study Start Date

2010-04-30

Study Completion Date

2012-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study is being conducted to assess the safety, tolerability and PK of AZD1480 in patients with advanced solid malignancies.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Phase I Study of AZD1480 in Patients With Advanced Solid Malignancies and Advanced Hepatocellular Carcinoma in the Escalation Phase,Non-Small Cell Lung Cancer(NSCLC) and Non-smokers With Lung Metastasis and Gastric Cancer and Solid Tumour in the Expansion Phase.

NCT01219543

Solid Tumour Advanced Solid Malignancies Child-Pugh A to B7 Advanced Hepatocellular Carcinoma +3 more

TERMINATED PHASE1

AZD5438 in Patients With Advanced Solid Malignancies

NCT00088790

Neoplasms

COMPLETED PHASE1

A Phase I Study of Safety, Tolerability, and PK of AZD2811 in Patients With Advanced Solid Tumors.

NCT02579226

Advanced Solid Tumours

COMPLETED PHASE1

Phase I, Open-Label, Dose-Escalation Study of AZD4877 in Solid Tumors

NCT00389389

Neoplasms

COMPLETED PHASE1

Safety, Tolerance, PK, and Anti-tumour Activity of AZD1775 Monotherapy in Patients With Advanced Solid Tumours

NCT02482311

Ovarian Cancer, TNBC, SCLC, Other Solid Tumours

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Solid Malignancies

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

AZD1480 until Maximum Tolerated Dose (MTD) is reached

Group Type EXPERIMENTAL

AZD1480

Intervention Type DRUG

continuous daily oral capsule

2

AZD1480 dose expansion of MTD

Group Type EXPERIMENTAL

AZD1480

Intervention Type DRUG

continuous daily oral capsule

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

AZD1480

continuous daily oral capsule

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients with advanced solid cancer without available therapy in the escalation phase and mutation positive NSCLC or non-smokers with other primary tumors lung metastasis in the expansion phase
* ECOG Performance Status 0-1
* Evidence of post-menopausal status in females or males willing to use barrier contraception

Exclusion Criteria

* Prior therapy with any JAK2 medications
* Significant lung disorder or lung disease. Previous radiation therapy to chest wall or chest infection requiring antibiotic treatment within 21 days before study screening. Evidence of significant pulmonary hypertension or COPD
* Eye disease of the cornea

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No